138 related articles for article (PubMed ID: 29145034)
1. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
Zhao K; Zhou X; Ding M
J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
Zhang J; Ji T
J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
[TBL] [Abstract][Full Text] [Related]
3. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
4. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Liu T; Wang Z; Guo P; Ding N
Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
Ding X; Liu X; Song X; Yao J
Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
[TBL] [Abstract][Full Text] [Related]
6. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
[TBL] [Abstract][Full Text] [Related]
8. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
[TBL] [Abstract][Full Text] [Related]
9. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
10. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
11. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
Yang Y; Qin J; Liu H; Yao X
J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
[TBL] [Abstract][Full Text] [Related]
13. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
[No Abstract] [Full Text] [Related]
15. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
16. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.
Tang HC; Chen YC
Int J Nanomedicine; 2015; 10():3131-46. PubMed ID: 25960652
[TBL] [Abstract][Full Text] [Related]
17. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.
Xu Z; Hu P; Fang D; Ni L; Xu J
J Mol Model; 2019 Jan; 25(1):13. PubMed ID: 30607513
[TBL] [Abstract][Full Text] [Related]
18. Biochemical Characterization of Full-Length Oncogenic BRAF
Cope N; Novak B; Candelora C; Wong K; Cavallo M; Gunderwala A; Liu Z; Li Y; Wang Z
Chembiochem; 2019 Nov; 20(22):2850-2861. PubMed ID: 31152574
[TBL] [Abstract][Full Text] [Related]
19. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
[TBL] [Abstract][Full Text] [Related]
20. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
Niu Y; Zhang Y; Yao X
Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
